LINCOLN

Lincoln Pharmaceuticals Share Price

₹673.55 +14.25 (2.16%)

05 Nov, 2024 17:34

SIP TrendupStart SIP in LINCOLN

Start SIP

Performance

  • Low
  • ₹655
  • High
  • ₹677
  • 52 Week Low
  • ₹535
  • 52 Week High
  • ₹812
  • Open Price₹661
  • Previous Close₹659
  • Volume18,385

Investment Returns

  • Over 1 Month + 1.59%
  • Over 3 Month + 2.61%
  • Over 6 Month + 12.67%
  • Over 1 Year + 22.24%
SIP Lightning

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.8
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 1,349
  • P/B Ratio
  • 2.3
  • Average True Range
  • 22.68
  • EPS
  • 46.1
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -9.68
  • RSI
  • 43.26
  • MFI
  • 37.88

Lincoln Pharmaceuticals Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations147.28142.49146.45155.99135.62
Total Income From Operations147.28142.49146.45155.99135.62
P/L Before Interest, Excpt. Items & Tax29.9222.7237.8737.2625.86
P/L Before Exceptional Items & Tax29.4822.2237.7136.8725.45
P/L After Tax from Ordinary Activities23.6718.6028.0427.6519.01
Net Profit/Loss For the Period23.6718.6028.0427.6519.01
IndicatorMar 24Mar 23
Revenue From Operations [Gross]571.22504.95
Revenue From Operations [Net]571.22504.95
Total Operating Revenues580.55510.31
Total Revenue614.97532.79
Total Expenses492.73432.34
Profit/Loss Before Tax122.24100.46
Profit/Loss For The Period93.3072.90
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity63.2439.16
Net Cash Used In Investing Activity-57.34-36.64
Net Cash Used in Finance Activity-5.18-4.50
Net Inc/Dec In Cash And Equivalent0.73-1.99
Cash And Equivalent End Of Year5.314.58
IndicatorMar 24Mar 23
Total Share Capital20.0320.03
Total Non-Current Liabilities15.1812.66
Total Current Liabilities92.1472.12
Total Capital And Liabilities700.15587.26
Total Non-Current Assets253.60220.26
Total Current Assets446.55367.00
Total Assets700.15587.26
Indicator20242023
EBIT Margin (%)21.3020.08
Return On Capital Employed (%)20.3419.89
Return On Equity (%)15.7314.50
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)295.98250.86
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations147.28142.49146.45155.99135.62
Total Income From Operations147.28142.49146.45155.99135.62
P/L Before Interest, Excpt. Items & Tax29.9222.7237.8737.2625.86
P/L Before Exceptional Items & Tax29.4822.2237.7136.8725.45
P/L After Tax from Ordinary Activities23.6718.6028.0427.6519.01
Net Profit/Loss For the Period23.6718.6028.0427.6519.01
IndicatorMar 24Mar 23
Revenue From Operations [Gross]571.22504.95
Revenue From Operations [Net]571.22504.95
Total Operating Revenues580.55510.31
Total Revenue614.97532.78
Total Expenses492.73432.30
Profit/Loss Before Tax122.24100.48
Profit/Loss For The Period93.3072.90
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity63.2239.26
Net Cash Used In Investing Activity-57.34-36.64
Net Cash Used in Finance Activity-5.18-4.50
Net Inc/Dec In Cash And Equivalent0.70-1.88
Cash And Equivalent End Of Year5.755.05
IndicatorMar 24Mar 23
Total Share Capital20.0320.03
Total Non-Current Liabilities15.1812.66
Total Current Liabilities92.2872.28
Total Capital And Liabilities700.29587.42
Total Non-Current Assets253.55220.21
Total Current Assets446.74367.21
Total Assets700.29587.42
Indicator20242023
EBIT Margin (%)21.3020.08
Return On Capital Employed (%)20.3419.89
Return On Equity (%)15.7314.50
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)295.98250.86

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹673.55
+ 14.25 (2.16%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹671.41
  • 50 Day
  • ₹680.07
  • 100 Day
  • ₹670.34
  • 200 Day
  • ₹639.63

Resistance and Support

662.43 Pivot Speed
  • R3 705.87
  • R2 692.43
  • R1 675.87
  • S1 645.87
  • S2 632.43
  • S3 615.87

Is Lincoln Pharmaceuticals Worth Buying?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally. Lincoln Pharmaceuticals has an operating revenue of Rs. 592.21 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-08-08 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-02 Quarterly Results
2023-08-10 Quarterly Results

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
5.19%
36.14%
8.89%
  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹673 As on 05 November, 2024 | 17:20

The Market Cap of Lincoln Pharmaceuticals is ₹1349.1 Cr As on 05 November, 2024 | 17:20

The P/E ratio of Lincoln Pharmaceuticals is 13.8 As on 05 November, 2024 | 17:20

The PB ratio of Lincoln Pharmaceuticals is 2.3 As on 05 November, 2024 | 17:20

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form